Ying Cheng

机构：Jilin Province Tumor Hospital, Flow Pharma (United States) · ORCID：0000-0002-8765-209X

发表论文 49 篇 · 总被引 1119 次 · h-index 15

代表论文

• ADRIATIC: Durvalumab (D) as consolidation treatment (tx) for patients (pts) with limited-stage small-cell lung cancer (LS-SCLC). (2024 · Journal of Clinical Oncology · 被引 48)
• A phase II study of efficacy and safety of the MEK inhibitor tunlametinib in patients with advanced NRAS-mutant melanoma (2024 · European Journal of Cancer · 被引 30)
• Dietary folic acid supplementation improves semen quality and spermatogenesis through altering autophagy and histone methylation in the testis of aged broiler breeder roosters (2021 · Theriogenology · 被引 24)
• Subcutaneous amivantamab vs intravenous amivantamab, both in combination with lazertinib, in refractory EGFR -mutated, advanced non-small cell lung cancer (NSCLC): Primary results, including overall survival (OS), from the global, phase 3, randomized controlled PALOMA-3 trial. (2024 · Journal of Clinical Oncology · 被引 18)
• Nuclear Fructose‐1,6‐Bisphosphate Inhibits Tumor Growth and Sensitizes Chemotherapy by Targeting HMGB1 (2023 · Advanced Science · 被引 15)
• Lazertinib Versus Osimertinib in Previously Untreated EGFR-Mutant Advanced NSCLC: A Randomized, Double-Blind, Exploratory Analysis From MARIPOSA (2025 · Journal of Thoracic Oncology · 被引 14)